World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   9 records for 1 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1
Recruitment statusMain ID Public TitleDate of Registration
RecruitingNCT02131272
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-005500-33-HUA trial investigating efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on metformin ± other oral antidiabetic drug(s) ± basal insulin25/06/2014
AuthorisedEUCTR2013-005500-33-HRA trial investigating efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on metformin ± other oral antidiabetic drug(s) ± basal insulin05/11/2014
AuthorisedEUCTR2013-005500-33-DEA trial investigating efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on metformin ± other oral antidiabetic drug(s) ± basal insulin19/09/2014
AuthorisedEUCTR2013-005500-33-ESA trial investigating efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on metformin ± other oral antidiabetic drug(s) ± basal insulin29/01/2015
Not RecruitingCTRI/2015/02/005545A Study to evaluate the Efficacy and Safety of Insulin Detemir against Insulin NPH along With Metformin and Diet/Exercise in Children and Adolescents having Type 2 Diabetes16-02-2015
02/05/2014
AuthorisedEUCTR2013-004392-12-SI
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-004392-12-SKEfficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes19/02/2014
AuthorisedEUCTR2013-004392-12-GBEfficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes30/04/2014
AuthorisedEUCTR2013-004392-12-HREfficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes03/09/2014
AuthorisedEUCTR2013-004392-12-NLEfficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes27/05/2014
AuthorisedEUCTR2013-004392-12-ROEfficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes30/05/2014
RecruitingCTRI/2014/09/005033A trial to evaluate the Efficacy and safety of semaglutide given once weekly versus insulin glargine given once daily as add on to metformin with or without sulphonylurea in subjects with type 2 diabetes ,who have not yet been treated with insulin.18-09-2014
Not recruitingNCT02128932Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes24/04/2014
13/02/2014
Not RecruitingCTRI/2013/09/003977
A Phase 3 Study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
12-09-2013
Not RecruitingEUCTR2012-000140-97-DE
The efficacy of insulin degludec/liraglutide as add-on therapy in controlling glycaemia in adults with type 2 diabetes inadequately controlled on sulphonylurea with or without metformin therapy 09/05/2012
RecruitingNCT01541215
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
Recruitment statusMain IDPublic titleDate of registration
RecruitingCTRI/2013/10/004082Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes21-10-2013
23/02/2012
Not recruitingNCT01313676
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingEUCTR2010-021638-72-DKStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 02/05/2011
AuthorisedEUCTR2010-021638-72-GRStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 05/09/2011
AuthorisedEUCTR2010-021638-72-ESStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease.18/11/2011
Not RecruitingEUCTR2010-021638-72-ITStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease.23/01/2012
AuthorisedEUCTR2010-021638-72-ATStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 05/04/2011
AuthorisedEUCTR2010-021638-72-LVStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 04/04/2011
AuthorisedEUCTR2010-021638-72-NLStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 19/09/2013
AuthorisedEUCTR2010-021638-72-BGStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 12/10/2011
AuthorisedEUCTR2010-021638-72-DEStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 11/04/2011
AuthorisedEUCTR2010-021638-72-GBStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 14/04/2011
AuthorisedEUCTR2010-021638-72-PLStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 11/05/2011
AuthorisedEUCTR2010-021638-72-CZStudy to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease 30/03/2011
Not RecruitingCTRI/2012/04/002563Study to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease who have history of cardiovascular disease.11-04-2012
03/02/2011
Not RecruitingEUCTR2009-016568-36-HU
Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2009-016568-36-ES 18/02/2010
AuthorisedEUCTR2009-016568-36-FR 16/04/2010
AuthorisedEUCTR2009-016568-36-GB 21/12/2010
AuthorisedEUCTR2009-016568-36-NL 10/02/2010
Not RecruitingEUCTR2009-016568-36-LVRandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO09/04/2010
Not RecruitingEUCTR2009-016568-36-GRRandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO09/03/2010
Not RecruitingEUCTR2009-016568-36-BGEffect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (TAO)24/09/2010
Not RecruitingEUCTR2009-016568-36-LTRandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO22/02/2010
Not RecruitingEUCTR2009-016568-36-ATRandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO13/04/2010
Not RecruitingEUCTR2009-016568-36-ITRandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO27/04/2010
Not RecruitingEUCTR2009-016568-36-EERandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO23/02/2010
Not RecruitingEUCTR2009-016568-36-PTRandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO15/02/2010
Not RecruitingEUCTR2009-016568-36-DERandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO25/02/2010
Not RecruitingEUCTR2009-016568-36-CZRandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO17/02/2010
Not RecruitingEUCTR2009-016568-36-BERandomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO08/02/2010
Not recruitingNCT01076764Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy25/02/2010
Not RecruitingCTRI/2010/091/000233Treatment of Acute Coronary syndrome with Otamixaban (TAO) 06-08-2010
02/02/2010
AuthorisedEUCTR2009-011360-10-ES
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2009-011360-10-FR 21/09/2009
AuthorisedEUCTR2009-011360-10-NOEffects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. - SIGNIFY09/03/2010
AuthorisedEUCTR2009-011360-10-GBEffects of ivabradine in patients with stable coronary artery disease without heart failure.17/08/2009
Not RecruitingEUCTR2009-011360-10-DEEffects of ivabradine in patients with stable coronary artery disease without heart failure25/09/2009
Not RecruitingEUCTR2009-011360-10-EEEffects of ivabradine in patients with stable coronary artery disease without heart failure07/10/2009
Not RecruitingEUCTR2009-011360-10-FIEffect of ivabradine in patients with stable coronary artery disease without heart failure18/08/2009
Not RecruitingEUCTR2009-011360-10-HUEffects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. - SIGNIFY04/09/2009
Not RecruitingEUCTR2009-011360-10-NLEffects of ivabradine in patients with stable coronary artery disease without heart failure18/08/2009
Not RecruitingEUCTR2009-011360-10-LTEffects of ivabradine in patients with stable coronary artery disease without heart failure24/09/2009
Not RecruitingEUCTR2009-011360-10-LVEffects of ivabradine in patients with stable coronary artery disease without heart failure19/08/2009
Not RecruitingEUCTR2009-011360-10-ATEffects of ivabradine in patients with stable coronary artery disease without heart failure.28/09/2009
Not RecruitingEUCTR2009-011360-10-GREffects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. - SIGNIFY06/10/2009
Not RecruitingEUCTR2009-011360-10-ITEffects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. - SIGNIFY01/10/2009
Not RecruitingEUCTR2009-011360-10-BEEffects of ivabradine in patients with stable coronary artery disease without heart failure.18/09/2009
Not RecruitingEUCTR2009-011360-10-SKEffects of ivabradine in patients with stable coronary artery disease without heart failure.11/09/2009
Not RecruitingEUCTR2009-011360-10-PTEffects of ivabradine in patients with stable coronary artery disease without clinical heart failure.07/08/2009
Not RecruitingEUCTR2009-011360-10-CZEffect of ivabradine in patients with stable coronary artery disease without heart failure09/09/2009
Not RecruitingEUCTR2009-011360-10-IEEffects of ivabradine in patients with stable coronary artery disease without heart failure 15/09/2009
Not RecruitingEUCTR2009-011360-10-BGEffects of ivabradine in patients with stable coronary artery disease without heart failure.19/11/2009
Not RecruitingEUCTR2009-011360-10-SEEffects of ivabradine in patients with stable coronary artery disease without heart failure28/09/2009
Not RecruitingEUCTR2009-011360-10-SIEffects of ivabradine in patients with stable coronary artery disease without heart failure19/10/2009
Not RecruitingEUCTR2009-011360-10-DKEffects of ivabradine in patients with stable coronary artery disease without heart failure.25/11/2009
Not RecruitingISRCTN61576291Effects of ivabradine in patients with stable coronary artery disease without heart failure21/09/2009
Not RecruitingCTRI/2010/091/000132A clinical trial with ivabradine in patients with stable coronary artery disease09-03-2010
Not recruitingNCT02446990Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure05/05/2015
07/08/2009
Not recruitingNCT00725985
Oral Cladribine in Early Multiple Sclerosis (MS)
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingEUCTR2008-003706-33-ESA Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS. Ensayo clínico de fase III, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, de cladribina oral en sujetos con un primer episodio clínico de alto riesgo de conversiòn a EM. - ORAl CLadribine in Early MS (ORACLE MS) Trial09/12/2008
Not RecruitingEUCTR2008-003706-33-GRA Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORAl CLadribine in Early MS (ORACLE MS) Trial12/03/2009
Not RecruitingEUCTR2008-003706-33-ATA Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORAl CLadribine in Early MS (ORACLE MS) Trial24/11/2008
Not RecruitingEUCTR2008-003706-33-NOA Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORAl CLadribine in Early MS (ORACLE MS) Trial09/12/2008
Not RecruitingEUCTR2008-003706-33-ITA Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORACLE Cladribine in Early MS (ORACLE MS)23/02/2009
AuthorisedEUCTR2008-003706-33-FRA Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORAl CLadribine in Early MS (ORACLE MS) Trial12/03/2009
Not RecruitingEUCTR2008-003706-33-CZClinical trial with oral cladribine in early Multiple Sclerosis (MS)22/10/2008
Not RecruitingEUCTR2008-003706-33-EEClinical trial with oral cladribine in early Multiple Sclerosis (MS)20/11/2008
AuthorisedEUCTR2008-003706-33-GBClinical trial with oral cladribine in early Multiple Sclerosis (MS)27/11/2008
Not RecruitingEUCTR2008-003706-33-FIClinical trial with oral cladribine in early Multiple Sclerosis (MS)10/11/2008
Not RecruitingEUCTR2008-003706-33-SEClinical trial with oral cladribine in early Multiple Sclerosis (MS)09/04/2009
Not RecruitingEUCTR2008-003706-33-PTA Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORAl CLadribine in Early MS (ORACLE MS) Trial17/12/2008
Not RecruitingEUCTR2008-003706-33-BGClinical trial with oral cladribine in early Multiple Sclerosis (MS)09/07/2009
Not RecruitingEUCTR2008-003706-33-DEClinical trial with oral cladribine in early Multiple Sclerosis (MS)09/12/2008
Not RecruitingEUCTR2008-003706-33-BEClinical trial with oral cladribine in early Multiple Sclerosis (MS)09/12/2008
Not RecruitingCTRI/2009/091/000061A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS28-01-2010
30/07/2008
    
1
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history